Refuge: Receptive CAR checkpoints
How Refuge is using CRISPR to suppress checkpoint genes in CAR T cells
Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety.
CEO Bing Wang told BioCentury that like endogenous T cells, CAR T cell therapies also express checkpoint proteins that can limit their anti-tumor activity.
Wang said Refuge designs its CARs to trigger checkpoint suppression by attaching a protease